deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 9-arm NCT04421820

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours

Sponsor: Bold Therapeutics, Inc.

Conditions Cholangiocarcinoma Colorectal Cancer Gastric Cancers Pancreatic Cancer
Interventions BOLD-100 +/- FOLFOX Chemotherapy (Arm VII) BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Updated 14 times since 2020 Last updated: Jan 23, 2026 Started: Aug 28, 2020 Primary completion: Jun 1, 2026 Completion: Sep 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Cholangiocarcinoma and Colorectal Cancer and is currently actively recruiting participants. Bold Therapeutics, Inc. leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Oct 2023 · 6 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Mar 2025 · 5 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

14 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Recruiting PHASE1/PHASE2

  3. Mar 2025 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Oct 2024 — Mar 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Status: Active Not Recruiting → Recruiting

▶ Show 9 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  2. Oct 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Apr 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  6. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  7. Jan 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  8. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Jul 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bold Therapeutics, Inc.
Data source: Bold Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations